Observed arrival · 2026-09-15
Satri-cel: A Field Guide to CAR-T's Solid-Tumour Breakthrough
A focused scientific resource explaining satri-cel, a Claudin18.2-targeting CAR-T therapy described as the first approved CAR-T treatment for a solid tumour.
Field notes
The resource follows satri-cel from target biology through cell engineering and clinical testing. It explains why Claudin18.2 is comparatively exposed on malignant gastric cells while remaining sealed within healthy stomach tissue, then identifies the construct as a humanised hu8E5-2I receptor with CD8α, CD28, and CD3ζ components. Its evidence section names the CT041-ST-01 randomised trial, reported as the first randomised CAR-T trial in a solid tumour, with 156 participants.
Observed signals
Read the marks
Editorial observations of this landing page, not a rating.
One card from the complete issue